Centre for Commercialization of Regenerative Medicine
- Open continuously
Overview
Access business services, regulatory expertise, technical services and a 40,000 square foot custom built facility for cell and gene therapy manufacturing in Toronto.
At a glance
Funding available
- Increase performance through digital transformation
- Develop a new product or service
- Optimize production processes
- Varies by project
- Open continuously
Eligible candidates
- Manufacturing
- Ontario
- For-profit business
- All revenue ranges
- All organization sizes
- Startups
Next Steps
Activities funded
This grant is focused on supporting the commercialization of regenerative medicine technologies by bridging the gap between academia and industry. It aims to address manufacturing challenges and enable the development, scaling, and execution of regenerative medicine projects.
- Assistance with process development and analytics for regenerative medicine innovations.
- Pre-clinical to commercial GMP-compliant manufacturing services for cell and gene therapies.
- Utilization of enabling technologies through industry partnerships to facilitate project development.
- Collaboration on unique intracellular delivery platforms for ex vivo cell-based therapies.
- Access to specialized infrastructure including Process Development Labs and GMP Clean Rooms.
- Support for comprehensive development and manufacturing plans tailored to specific project needs.
Eligibility
Who is eligible?
The context provided does not detail specific eligibility criteria for a grant application directly related to CCRM's services. However, typically, the type of entities that may be interested in reaching out or exploring collaboration with CCRM include companies or research entities at the interface of academia and industry that are focused on cell and gene therapy manufacturing, require process development, and are aiming to transition from pre-clinical to GMP-compliant manufacturing stages. These may include small biotechs, large pharmaceutical companies, or research organizations involved in developing innovative therapies. Prospective partners are likely engaged in:- Manufacturing challenges needing technical support or solutions.- Cell and gene therapy development.- Seeking to scale from pre-clinical to commercial manufacturing.- Engaging in collaborative processes for technological and manufacturing development.- Needing infrastructure and resources for GMP-compliance and process continuity from lab to market.
Eligible expenses
The activities eligible for this grant are focused on addressing manufacturing challenges and advancing manufacturing processes for cell and gene therapies. This involves collaboration and utilization of specialized infrastructure and technologies to streamline production and ensure compliance with industry standards.
- Tackling manufacturing challenges at the interface between academia and industry.
- Accessing process development and analytics services for cell and gene therapies.
- Availing pre-clinical to commercial GMP-compliant manufacturing services.
- Collaborating with an industry-leading team, including 55+ PhDs, for specialized expertise.
- Using enabling technologies through industry partnerships for advanced manufacturing solutions.
Additional information
Here are additional relevant details for this grant:
- The collaboration with CCRM provides access to 55+ PhDs, ensuring significant specialized expertise to support projects.
- CCRM boasts state-of-the-art facilities that are accessible for remote viewing, which can provide potential applicants with an insight into the possibilities for their projects.
- CCRM has a strong track record, having supported three IND filings since 2019, indicating a proven capacity to aid in regulatory processes.
- The collaboration with CCRM includes co-located process development and GMP-compliant manufacturing, ensuring seamless transition and process continuity from lab development to full-scale production.
- Customer testimonials showcase successful collaborations, reflecting CCRM's effectiveness in improving manufacturing timelines and processes.